In addition, our clinicopathological correlation analysis revealed that the low expression of SPARCL1 is related to age, TNM stage, ER status, PR status, histological type, molecular type, and survival status of patients with BC, while younger age, higher TNM stage, HR-negative status, and basal-like type were among the unfavorable phenotypes in patients with BC. This evidence concerns the gene SPARCL1 and breast cancer.